{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05892718",
            "orgStudyIdInfo": {
                "id": "HCB101-101"
            },
            "organization": {
                "fullName": "FBD Biologics Limited",
                "class": "INDUSTRY"
            },
            "briefTitle": "A Safety and Efficacy Study of HCB101, Fc-fusion Protein Targeting SIRP\u03b1-CD47 Pathway, in Solid or Hematological Tumors",
            "officialTitle": "A Phase 1, Open-label, Multi-center, Dose Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of HCB101 in Subjects With Advanced Solid Tumors or Relapsed and Refractory Non-Hodgkin Lymphoma",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "a-safety-and-efficacy-study-of-fc-fusion-protein-targeting-pathway-in-solid-or-hematological-tumors"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-04",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2023-10-02",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-05-30",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-11-15",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-05-09",
            "studyFirstSubmitQcDate": "2023-05-28",
            "studyFirstPostDateStruct": {
                "date": "2023-06-07",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-04-18",
            "lastUpdatePostDateStruct": {
                "date": "2024-04-19",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "FBD Biologics Limited",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The purpose of this study is to find out whether IV injection of HCB101 is an effective treatment for different types of advanced solid tumors or relapsed and refractory non-Hodgkin lymphoma and what side effects (unwanted effects) may occur in subjects aged 18 years old and above.",
            "detailedDescription": "This is an open-label, multi-center, dose-escalation, Phase 1 study. This study is to evaluate the safety, tolerability, pharmacokinetics (PK), anti-tumor activity, and identification of maximum tolerated dose (MTD) of HCB101 intravenous injection in adults with advanced solid tumors or relapsed and refractory non-Hodgkin lymphoma.\n\nEligible subjects must have failed standard therapies, been intolerable, or been considered medically inappropriate by the investigator. Subjects will be treated until unacceptable AEs, radiographic or clinical documented disease progression, withdrawal of consent, loss to follow-up, death, or termination of the study, whichever occurs first."
        },
        "conditionsModule": {
            "conditions": [
                "Advanced Solid Tumor",
                "Refractory Non-Hodgkin Lymphoma"
            ],
            "keywords": [
                "Immunotherapy",
                "CD47",
                "SIRP\u03b1",
                "Solid Tumor",
                "Lymphoma"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SINGLE_GROUP",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 60,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "HCB101",
                    "type": "EXPERIMENTAL",
                    "description": "HCB101 in subjects with advanced solid tumors or relapsed and refractory non-Hodgkin lymphoma.\n\nDosage levels: 0.08 mg/kg, 0.16 mg/kg, 0.32 mg/kg, 0.64 mg/kg, 1.28 mg/kg, 2.56 mg/kg, and 5.12 mg/kg sequentially.",
                    "interventionNames": [
                        "Drug: HCB101"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "HCB101",
                    "description": "HCB101 administered via. intravenous (IV) infusion.",
                    "armGroupLabels": [
                        "HCB101"
                    ],
                    "otherNames": [
                        "SIRP\u03b1-Fc fusion protein"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Number/incidence and percentage of subjects with adverse events, including ADA.",
                    "description": "To evaluate the safety and tolerability of HCB101",
                    "timeFrame": "12 months"
                },
                {
                    "measure": "Number of subjects with MTD of HCB101",
                    "description": "To evaluate the safety and tolerability of HCB101",
                    "timeFrame": "12 months"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Overall Rate Response (ORR)",
                    "description": "ORR is defined as the proportion of participants who have a partial response (PR) or critical response (CR)",
                    "timeFrame": "12 months"
                },
                {
                    "measure": "Duration of Response (DoR)",
                    "description": "DOR is defined as time from date of initial documentation of a response (PR or CR) to date of first documented evidence of progressive disease (PD)",
                    "timeFrame": "12 months"
                },
                {
                    "measure": "Disease Control Rate (DCR)",
                    "description": "DCR is defined as the proportion of participants who have a partial response (PR), critical response (CR), or disease stable (SD)",
                    "timeFrame": "12 months"
                },
                {
                    "measure": "Progression-Free Survival (PFS)",
                    "description": "Defined as the duration from the start of treatment until tumor progression or death of any cause.",
                    "timeFrame": "12 months"
                },
                {
                    "measure": "Peak Plasma Concentration (Cmax) of HCB101",
                    "description": "Peak Plasma Concentration (Cmax) of HCB101 following single and repeated IV doses of HCB101 at different dose levels.",
                    "timeFrame": "12 months"
                },
                {
                    "measure": "Area under the plasma concentration versus time curve (AUC) of HCB101",
                    "description": "Area under the plasma concentration versus time curve (AUC) of HCB101 following single and repeated IV doses of HCB101 at different dose levels.",
                    "timeFrame": "12 months"
                },
                {
                    "measure": "Time to maximum drug concentration in plasma (Tmax) of HCB101",
                    "description": "Time to maximum drug concentration in plasma (Tmax) of HCB101 following single and repeated IV doses of HCB101 at different dose levels.",
                    "timeFrame": "12 months"
                },
                {
                    "measure": "Terminal elimination half-life (t1/2) of HCB101",
                    "description": "Terminal elimination half-life (t1/2) of HCB101 following single and repeated IV doses of HCB101 at different dose levels.",
                    "timeFrame": "12 months"
                }
            ],
            "otherOutcomes": [
                {
                    "measure": "CD47 receptor occupancy on circulating red blood cells (RBCs)",
                    "description": "CD47 receptor occupancy on circulating red blood cells (RBCs) will be measured as an indication of target engagement.",
                    "timeFrame": "12 months"
                },
                {
                    "measure": "Concentration of potential PD biomarkers in participants will be assess.",
                    "description": "Changes in macrophage function related cytokines will be assess after HCB101 treatment.",
                    "timeFrame": "12 months"
                },
                {
                    "measure": "ctDNA detection",
                    "description": "ctDNA detection in participants using next-generation sequencing (NGS ).",
                    "timeFrame": "12 months"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n1. Able to understand and willing to sign the ICF.\n2. Male and female subjects of \u226518 years of age.\n3. Histologically/cytologically confirmed, locally advanced solid tumor: subjects with histologically or cytologically confirmed advanced solid tumors refractory to standard therapy, or for which no standard treatment exists or non-Hodgkin lymphoma, relapsed or refractory to at least 2 prior lines of therapy.\n4. For subjects with advanced solid tumor - must have at least 1 measurable lesion as defined by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 at baseline.\n5. For subjects with non-Hodgkin lymphoma - must have non-Hodgkin lymphoma that is measurable or assessable for response per Lugano Classification (with 2016 refinement).\n6. Must have ECOG performance status of 0 to 2 at Screening.\n7. Able to provide tumor tissue samples.\n8. Have life expectancy of \u226512 weeks.\n\nExclusion Criteria:\n\n1. With known history of hypersensitivity to any components of HCB101.\n2. Known active or untreated CNS metastases and/or carcinomatous meningitis.\n3. Have undergone a major surgery or radical radiotherapy or palliative radiotherapy or have used a radioactive drug that is not completed at least 2 weeks prior to the first dose of HCB101.\n4. Clinically significant cardiovascular condition.\n5. Any previous treatment-related toxicities which have not recovered to \u2264 Grade 1 as evaluated by National Cancer Institute, Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0 or baseline, except alopecia and anemia.\n6. With known inherited or acquired bleeding disorder or bleeding diathesis. .\n7. Have RBC transfusion within 4 weeks prior to Screening.\n8. With a previously documented diagnosis of hemolytic anemia or Evans Syndrome in the last 3 months.\n9. Any investigational or approved systemic cancer therapy.\n10. Active use of vitamin K antagonist anticoagulant like warfarin. Use of low molecular weight heparin and factor Xa inhibitors will be permitted on case by case basis. There will be no restriction for daily aspirin \u2264 81 mg/QD.\n11. Have used herbal medication within 14 days prior to the first dose of HCB101.\n12. Have received any treatment targeting the CD47 or SIRP\u03b1 pathway.\n13. Have other malignancies requiring treatment within 2 years prior to the first dose of HCB101.\n14. Participation in another clinical study with an investigational product administered in the last 14 days prior to receiving the first dose of HCB101.\n15. An investigational device used within 28 days prior to the first dose of HCB101.\n16. Positive for hepatitis B, active hepatitis C infections, positive for HIV, or known active or latent tuberculosis.\n17. Known to have a history of alcoholism or drug abuse.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "FBD Clinical",
                    "role": "CONTACT",
                    "phone": "+886-2-27921366",
                    "email": "HCB101-101@hanchorbio.com"
                }
            ],
            "locations": [
                {
                    "facility": "Hematology-Oncology Associates of the Treasure Coast",
                    "status": "RECRUITING",
                    "city": "Port Saint Lucie",
                    "state": "Florida",
                    "zip": "34952",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Christine Gerdes",
                            "role": "CONTACT",
                            "phone": "772-408-5159"
                        },
                        {
                            "name": "Nicholas Iannotti, Dr.",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 27.29393,
                        "lon": -80.35033
                    }
                },
                {
                    "facility": "Carolina BioOncology",
                    "status": "RECRUITING",
                    "city": "Huntersville",
                    "state": "North Carolina",
                    "zip": "28078",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Ashley Wallace",
                            "role": "CONTACT",
                            "phone": "980-441-1021"
                        },
                        {
                            "name": "John Powderly, Dr.",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 35.41069,
                        "lon": -80.84285
                    }
                },
                {
                    "facility": "Greenville Hospital System University Medical Center (ITOR)",
                    "status": "RECRUITING",
                    "city": "Greenville",
                    "state": "South Carolina",
                    "zip": "29605",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Jill Roemmich",
                            "role": "CONTACT",
                            "phone": "864-455-3600"
                        },
                        {
                            "name": "Jeffery Edenfield, Dr.",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 34.85262,
                        "lon": -82.39401
                    }
                },
                {
                    "facility": "UT Southwestern Medical Center",
                    "status": "RECRUITING",
                    "city": "Dallas",
                    "state": "Texas",
                    "zip": "75390",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Shannon Garcia",
                            "role": "CONTACT",
                            "phone": "214-648-4118"
                        },
                        {
                            "name": "Tian Zhang, Dr.",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 32.78306,
                        "lon": -96.80667
                    }
                },
                {
                    "facility": "Taipei Medical University - Shuang Ho Hospital, Ministry of Health and Welfare",
                    "status": "RECRUITING",
                    "city": "New Taipei City",
                    "zip": "23561",
                    "country": "Taiwan",
                    "contacts": [
                        {
                            "name": "Yu-Yan Hong",
                            "role": "CONTACT",
                            "phone": "886-2-22490088",
                            "phoneExt": "8767"
                        },
                        {
                            "name": "Wei-Hong Cheng, Dr.",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 25.01111,
                        "lon": 121.44583
                    }
                },
                {
                    "facility": "National Taiwan University Hospital",
                    "status": "RECRUITING",
                    "city": "Taipei",
                    "zip": "10002",
                    "country": "Taiwan",
                    "contacts": [
                        {
                            "name": "Chia-Hsuan Yang",
                            "role": "CONTACT",
                            "phone": "886-2-23123456",
                            "phoneExt": "68057"
                        },
                        {
                            "name": "Chia-Chi Lin, Dr.",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 25.04776,
                        "lon": 121.53185
                    }
                },
                {
                    "facility": "Taipei Veterans General Hospital",
                    "status": "RECRUITING",
                    "city": "Taipei",
                    "zip": "11217",
                    "country": "Taiwan",
                    "contacts": [
                        {
                            "name": "Pei-Ling Chiu",
                            "role": "CONTACT",
                            "phone": "886-2-28757270 ext 2999"
                        },
                        {
                            "name": "Mu-Hsin Chang, Dr.",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 25.04776,
                        "lon": 121.53185
                    }
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000008223",
                    "term": "Lymphoma"
                },
                {
                    "id": "D000008228",
                    "term": "Lymphoma, Non-Hodgkin"
                }
            ],
            "ancestors": [
                {
                    "id": "D000009370",
                    "term": "Neoplasms by Histologic Type"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000008232",
                    "term": "Lymphoproliferative Disorders"
                },
                {
                    "id": "D000008206",
                    "term": "Lymphatic Diseases"
                },
                {
                    "id": "D000007160",
                    "term": "Immunoproliferative Disorders"
                },
                {
                    "id": "D000007154",
                    "term": "Immune System Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M11220",
                    "name": "Lymphoma",
                    "asFound": "Lymphoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M21314",
                    "name": "Hematologic Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M11222",
                    "name": "Lymphoma, Non-Hodgkin",
                    "asFound": "Non-Hodgkin Lymphoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M12315",
                    "name": "Neoplasms by Histologic Type",
                    "relevance": "LOW"
                },
                {
                    "id": "M11225",
                    "name": "Lymphoproliferative Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M11203",
                    "name": "Lymphatic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M10206",
                    "name": "Immunoproliferative Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M10200",
                    "name": "Immune System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "T3543",
                    "name": "Lymphosarcoma",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC15",
                    "name": "Blood and Lymph Conditions"
                },
                {
                    "abbrev": "BC20",
                    "name": "Immune System Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M2853",
                    "name": "Immunomodulating Agents",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}